Headache and Migraine

NeuroOne's OneRF system, already cleared for functional neurosurgery, is now being evaluated by the FDA for trigeminal nerve ablation to treat chronic facial pain.

Neurology News Network. for the week ending April 19, 2025. [WATCH TIME: 3 minutes]

In a randomized cross-over trial, 4 of 5 commonly used drugs for idiopathic intracranial hypertension reduced intracranial pressure; however, also exacerbated cognitive issues.

A recently published phase 1 study revealed that coadministration of intranasal zavegepant with an oral contraceptive did not lead to clinically significant changes in drug exposure.

Although the study reported no evidence linking human leukocyte antigen alleles to migraine, the findings were not replicated, suggesting the HLA system may not be involved in migraine susceptibility.

Afterimage duration was more prolonged in patients with migraine with aura than those without, suggesting differing underlying pathophysiology between the two subtypes despite the exact mechanisms remaining unclear.

CT-132, an approach that aims to reduce brain hypersensitivity, becomes the first marketed digital treatment to prevent migraine, intended to be used with other previously approved medications.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 11, 2025.

Cleveland Clinic’s $1.1 billion Neurological Institute, opening in 2027, will revolutionize neurological care with a state-of-the-art, patient-centered design integrating advanced technology and innovative care solutions.

Relative to previously approved therapies like rimegepant, ubrogepant, and zavegepant, AXS-07 resulted in better 2-hour pain relief, sustained pain relief, and reduced use of rescue medications.

The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]

Teva’s migraine therapy fremanezumab (Ajovy) may soon expand its reach to pediatric patients, as the FDA reviews a supplemental application for its use in children and adolescents aged 6 to 17.

Findings showed that atogepant 60 mg once daily demonstrated significant improvements in functional outcomes for patients with episodic migraine, compared with placebo, over 12 weeks.

A recent analysis of the PRODROME trial explored the impact of ubrogepant, an FDA-approved acute treatment of migraine with or without aura, on patient-reported outcomes in migraine management.

A recent case-control study suggests that although sleep bruxism may not be directly associated with migraine in patients with temporomandibular disorders, mixed bruxism episodes occur more frequently in those with migraine.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CGRP medications to treat migraine.

Findings demonstrated that fremanezumab significantly reduced the use of acute headache medications and the frequency of migraine-associated symptoms in patients with episodic migraine compared with placebo.

AHN Neuroscience Institute is using advanced, minimally invasive spinal surgery techniques to treat complex spine conditions, offering faster recovery, smaller incisions, and improved patient outcomes.

Erenumab (Aimovig) effectively reduced chronic headaches in a patient with a history of aneurysmal subarachnoid hemorrhage, showcasing the therapeutic potential of CGRP-targeting treatments for post-aSAH headaches.

Findings from a recently published large-scale analysis highlighted the high burden of cognitive impairment among veterans with both migraine and TBI.

New research highlights the significant economic burden of misdiagnosed migraine patients, revealing higher healthcare costs and resource utilization over time compared to those with accurate diagnoses.

Explore the key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more in this essential feature.

Treatment with the Chordate System led to a significantly greater reduction in monthly headache days during the performance assessment period, with a reduction of 3.5 days compared to 1.2 days in the sham group.

Using more than 100,000 claims, the 36-month cumulative risk of acute myocardial infarction and stroke was similar between erenumab and other anti-CGRP mAbs, with minimal residual bias.

Propranolol showed a stronger protective effect against ischemic stroke compared to other beta-blockers, such as metoprolol and timolol, possibly due to its unique pharmacological profile.